Development of novel trispecific immunoligands (triplebodies) to retarget natural killer cells against chronic lymphocytic leukemia [PDF]
Chronic lymphocytic leukemia of B cells (B-CLL or CLL) involves malignant transformation of mature B lymphocytes and is characterized by accumulation of CD19+ CD5+ monoclonal B cells.
Vyas, Maulik
core
Background Breast cancer (BRCA) is a malignancy originating in the breast cells, characterized by a poor overall survival rate. Post-resection, chemotherapy is commonly recommended as a primary therapeutic approach; however, its efficacy remains limited.
Zhaofeng Ma, Man Zheng, Pulin Liu
doaj +1 more source
Breast cancer (BC) is the most prevalent cancer in women globally. The tumor microenvironment (TME), comprising epithelial tumor cells and stromal elements, is vital for breast tumor development.
Lizhao Wang +6 more
doaj +1 more source
Epigenetic modulation of NKG2D ligands enhances NKG2D-CAR T cell efficacy in neuroblastoma. [PDF]
Navarro-Zapata A +20 more
europepmc +1 more source
Das maligne Melanom stellt die tödlichste Form aller Hautkrebserkrankungen dar und entsteht durch eine maligne Transformation der Melanozyten. Melanomzellen können durch zytotoxische Lymphozyten, wie NK Zellen und T Zellen als entartet erkannt und ...
Baingo, Jolanthe
core
Nuclear EGFR Block Expression of MHC Class-I Related Genes Necessary for Natural Killer Cell Recruitment and Cytotoxicity [PDF]
Nuclear Epidermal Growth Factor Receptor (nEGFR) driven triple negative breast cancer (TNBC) can exhibit therapeutic resistance and immune evasion in vivo, making treatment difficult.
Crane, Sara
core +1 more source
Combinatorial therapy with resveratrol sensitizes glioblastoma to NKG2D CAR-T cells. [PDF]
Liang W +8 more
europepmc +1 more source
cGAS/STING-mediated upregulation of NKG2D ligands in LSCs contributes to enhanced sensitivity to NK cells. [PDF]
Ouyang Y, Qin Y, Zhang Q, Zhu P, Zhu H.
europepmc +1 more source
NKGD2 Ligands (NKG2DLs) in Breast Cancer: In Silico Analysis and Narrative Review. [PDF]
Peña-López J +13 more
europepmc +1 more source
EVOLVE platform, a trispecific T cell engager with integrated CD2 costimulation, for the treatment of solid and hematologic tumors. [PDF]
Sergeeva OA +24 more
europepmc +1 more source

